Clinical Trials Logo

Placenta Previa clinical trials

View clinical trials related to Placenta Previa.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06030492 Recruiting - Placenta Accreta Clinical Trials

Efficacy of Hydrogen Peroxide ( H2O2) in Controlling Placental Site Bleeding in Caesarian Delivery for Placenta Previa / Accreta Spectrum ( PAS)

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

Placenta accreta spectrum (PAS), encompassing the terms placenta accreta, increta, and percreta; abnormally invasive placenta; morbidly adherent placenta; and invasive placentation, is a leading cause of life-threatening obstetric haemorrage (1) . Currently, more than 90% of women diagnosed with PAS also have a placenta praevia (2), and the combination of both conditions leads to high maternal morbidity and mortality due to massive haemorrhage at the time of birth . Maternal mortality of placenta praevia with percreta has been reported to be as high as 7% of cases . Hydrogen peroxide is well-known for its antimicrobial and antiseptic properties. It is used to clean surgical cuts for better localization of bleeding focus in surgery and orthopedics and burn excisions to induce hemostasis . Topical application of hydrogen peroxide was proven to induce hemostasis and reduce operative time in both tonsillectomy and adenoidectomy .

NCT ID: NCT06030479 Recruiting - Placenta Accreta Clinical Trials

Topical Adrenaline Versus Warm Saline Solution for Minimizing Intraperitoneal Bleeding During Caesarian Delivery for Placenta Previa / Accreta Spectrum ( PAS)

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

Placenta accreta spectrum (PAS), encompassing the terms placenta accreta, increta, and percreta; abnormally invasive placenta; morbidly adherent placenta; and invasive placentation, is a leading cause of life-threatening obstetric haemorrage . Currently, more than 90% of women diagnosed with PAS also have a placenta praevia , and the combination of both conditions leads to high maternal morbidity and mortality due to massive haemorrhage at the time of birth . Maternal mortality of placenta praevia with percreta has been reported to be as high as 7% of cases . Adrenaline has also been demonstrated to be a reasonable hemostatic agent because of its low cost, low risk, powerful vasoconstrictor, and platelet aggregation. Topical use of adrenaline is an effective and reasonable hemostatic agent in tonsillectomy.

NCT ID: NCT05811676 Recruiting - Placenta Previa Clinical Trials

Tranexamic Acid for the Prevention of Postpartum Hemorrhage in Pregnant Women With Placenta Previa

TRAPP
Start date: July 12, 2023
Phase: Phase 3
Study type: Interventional

Many RCT(randomized controlled trial) studies reported that tranexamic acid reduced blood loss in women who had elective cesareans. However, most of these elective cesareans are without high-risk factors of postpartum hemorrhage, such as placenta previa. The prophylactic use of tranexamic acid in the placenta previa is not clear. studies had poor quality and lacked adequate power to assess severe adverse events.

NCT ID: NCT05802251 Recruiting - Placenta Previa Clinical Trials

Sonographic Parameters and Risk of Antepartum Hemorrhage in Asymptomatic Women With Placenta Previa: A Cohort Study

Start date: June 1, 2022
Phase:
Study type: Observational

The aim of this study is to evaluate the effectiveness of ultrasonographic parameters (cervical length, placental thickness and distance placental edge from internal os of the cervix) in predicting the risk of antepartum hemorrhage and emergency cesarean delivery in asymptomatic women with placenta previa.

NCT ID: NCT04609527 Recruiting - Placenta Accreta Clinical Trials

Management of Placenta Accreta Spectrum

Start date: October 16, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

placenta accreta spectrum is group of disorders which have a depate about the best way of management. this is a descriptive study about the best techniques to reduce morbidity and mortalities related to it.

NCT ID: NCT04518163 Recruiting - Placenta Previa Clinical Trials

Bakri Balloon Plus Tranexamic Acid During Cesarean Delivery for Placenta Previa

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

Objective to investigate the effect of adjunctive intravenous tranexamic acid (TA) on blood loss during cesarean section (CS) in patients with placenta previa undergone Bakri balloon tamponade

NCT ID: NCT04518150 Recruiting - Placenta Previa Clinical Trials

Combined Bilateral Uterine Artery Ligation and Bakri Balloon During Cesarean Section

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

This study will be performed to compare the effectiveness of routine Bakri balloon tamponade and Bilateral Uterine Artery Ligation during cesarean section in patients with placenta previa

NCT ID: NCT04350645 Recruiting - Clinical trials for Hemorrhage From Placenta Previa, With Delivery

Role of Prophylactic Tranexamic Acid in Reducing Blood Loss During Elective Caesarean Section for Placenta Praevia Major

Start date: March 24, 2020
Phase: N/A
Study type: Interventional

Prophylactic tranexamic acid will reduce blood loss during Caesarean section for placenta praevia

NCT ID: NCT04304625 Recruiting - Clinical trials for Postpartum Hemorrhage

TRAnexamic Acid for Preventing Blood Loss Following a Cesarean Delivery in Women With Placenta pREVIA

TRAAPrevia
Start date: August 7, 2020
Phase: Phase 3
Study type: Interventional

Several randomized, controlled trials, mostly involving women undergoing cesarean delivery, have shown that the prophylactic intravenous administration of 1 g of tranexamic acid after childbirth reduced blood loss. Most were small, single-centre trials with considerable methodologic limitations. It is important to emphasize that none of these RCTs has included women at increased risk of PPH such as placenta previa, a context in which the prevalence of moderate and severe blood loss is significantly higher and where the magnitude of the effect of TXA may highly differ compared to low risk women

NCT ID: NCT04055194 Recruiting - Placenta Previa Clinical Trials

Antenatal Tranexamic Acid in Women With Symptomatic Placenta Previa

Start date: August 1, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

200 pregnant women with symptomatic placenta previa with previous bleeding attacks attending Ain Shams University maternity hospital will be recruited and randomized to receive either tranexamic acid tablets (500mg four times daily) or placebo. Amount of bleeding during antepartum bleeding attacks will be estimated (by hemoglobin change from baseline at admission till delivery).